Mereo BioPharma’s Q3 2025: Progress in Rare Disease Pipeline

Mereo Biopharma ( (MREO) ) has released its Q3 earnings. Here is a breakdown of the information Mereo Biopharma presented to its investors.

Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases, with a portfolio that includes setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2.

In its third-quarter 2025 earnings report, Mereo BioPharma highlighted significant progress in its clinical programs, particularly the Phase 3 Orbit and Cosmic studies of setrusumab, which are expected to yield results by the end of 2025. The company also emphasized its strategic partnerships and retained commercial rights in Europe for vantictumab.

Financially, Mereo reported a net loss of $7.0 million for the third quarter of 2025, a significant improvement from the $15.0 million loss in the same period last year. The company’s cash reserves stood at $48.7 million, which are projected to sustain operations into 2027. Research and development expenses increased to $4.3 million, driven by ongoing clinical activities, while general and administrative expenses slightly decreased to $6.0 million.

Looking ahead, Mereo BioPharma remains focused on advancing its clinical trials and securing partnerships to support the commercialization of its therapies. The management is optimistic about the potential impact of its pipeline on rare disease treatment, with key milestones anticipated in the near future.